Get in touch

Chronic Kidney Disease and High Blood Pressure Study

See how you can participate

MediSphere is conducting a Phase III, randomized, double-blinded study to assess the efficacy, safety and tolerability of Baxdrostat in combination with Dapagliflozin compared with Dapagliflozin alone on Chronic Kidney Disease (CKD) progression in participants with CKD and high blood pressure. The effective management of high blood pressure may delay CKD progression.

You may qualify if:

you are 18 years of age and older,
have CKD,
high blood pressure and are on an ACE inhibitor or ARB.

High blood pressure (HBP also called hypertension) is the second most common cause of chronic kidney disease (CKD). According to the American Kidney Fund about 1 in 4 people with CKD have it because of high blood pressure. More treatment options are needed to slow down CKD progression and keep high blood pressure under control.

Do you want to help advance chronic kidney disease and high blood pressure medical research? Consider enrolling in a clinical study aiming to discover potential new treatment options for individuals with CKD and high blood pressure.

The BaxDuo-Arctic study is being conducted to determine if a combination investigational treatment of baxdrostat with dapagliflozin (BaxDuo) may work better at lowering your blood pressure and slowing CKD progression than dapagliflozin alone.

Baxdrostat is an investigational medication that is designed to reduce the levels of a hormone called aldosterone. Aldosterone tells your kidneys to store fluid, which may increase your blood pressure. It is thought that reducing the levels of this hormone may help lower blood pressure, protect kidneys, and slow down CKD progression. Baxdrostat is not an approved CKD treatment. It is still being tested in studies like this one.

Dapagliflozin is approved for the treatment of CKD and is designed to block a protein called SGLT2. SGLT2 helps regulate glucose (sugar) levels in the blood by moving glucose from the urine back into the bloodstream. Dapagliflozin blocks SGLT2, which helps to protect your kidneys.